How to use the defective product report to notify a quality defect to the Romanian Drug Agency
1234
post-template-default,single,single-post,postid-1234,single-format-standard,bridge-core-3.3.2,cookies-not-set,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-smooth-scroll-enabled,qode-child-theme-ver-1.0.0,qode-theme-ver-30.8.2,qode-theme-bridge,wpb-js-composer js-comp-ver-7.9,vc_responsive

15 Nov How to use the defective product report to notify a quality defect to the Romanian Drug Agency

Posted at 11:46h in GMP/GDP, Regulatory Affairs by

The Romanian Drug Agency (ANMDM) published on their website scientific decision No 4/24.10.2018 implementing the document of European Medicines Agency (EMA) on the defective product report (EMA/INS/GMP/35037/2017). Marketing authorisation holders (MAHs) have to report to ANMDM all the non-conformities related to the quality of medicinal products authorised in Romania under MRP/DCP or purely national procedure. The adopted national reporting form is similar to the one proposed by EMA and has to be sent to ANMDM by e-mail. ANMDM’s recommendation is to have the details of a contact person for Romania included in the reporting e-mail in case additional information is required.

Our experts are able to assist MAHs in reporting quality defects to ANMDM.